Cochrane · systematic review · CD007649
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Ruiz Garcia, V, Burls, A, Cabello, JB, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCertolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX) for rheumatoid arthritis in adults
Population: patients with rheumatoid arthritis in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50% improvement Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 3.8 [2.42, 5.95] | 5 studies · 1445 participants | High |
HAQ change from baseline Scale from: 0 to 3. Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 4 studies · 1268 participants | Moderate Downgraded: risk of bias |
Proportion of patients achieving DAS < 2.6 (remission) Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 2.94 [1.64, 5.28] | 6 studies · 2420 participants | High |
Radiological changes: Erosion Scores (ES) Scale from: 0 to 230 Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 2 studies · 714 participants | Moderate Downgraded: risk of bias |
Serious adverse events Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | Peto OR 1.47 [1.13, 1.91] | 9 studies · 3927 participants | High |
All Withdrawals: All doses of certolizumab pegol vs placebo Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 0.47 [0.39, 0.56] | 13 studies · 5200 participants | Moderate Downgraded: risk of bias, inconsistency |
Withdrawals due to adverse events All doses of certolizumab pegol versus placebo Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | Peto OR 1.45 [1.09, 1.94] | 12 studies · 5236 participants | High |
Certolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX) for rheumatoid arthritis in adults
Population: patients with rheumatoid arthritis in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50% improvement Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 3.8 [2.42, 5.95] | 5 studies · 1445 participants | Moderate Downgraded: risk of bias |
HAQ change from baseline Scale from: 0 to 3. Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 4 studies · 1268 participants | Moderate Downgraded: risk of bias |
Proportion of patients achieving DAS <2.6 (remission) Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 8.47 [4.15, 17.28] | 4 studies · 1381 participants | Moderate Downgraded: risk of bias |
Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 2 studies · 859 participants | Moderate Downgraded: risk of bias |
Serious adverse events Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | Peto OR 1.77 [1.27, 2.46] | 7 studies · 2729 participants | Moderate Downgraded: risk of bias |
All Withdrawals: All doses of certolizumab pegol vs placebo Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 0.42 [0.36, 0.5] | 10 studies · 3962 participants | Moderate Downgraded: risk of bias |
Withdrawals due to adverse events All doses of certolizumab pegol versus placebo Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | Peto OR 1.66 [1.15, 2.37] | 9 studies · 3998 participants | Moderate Downgraded: risk of bias |
Summary of findings certolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX) for rheumatoid arthritis in adults
Population: patients with rheumatoid arthritis in adults
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50% improvement Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 6.01 [3.84, 9.4] | 2 studies · 965 participants | High |
HAQ change from baseline Scale from: 0 to 3. Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 2 studies · 965 participants | High |
Serious adverse events Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | OR 2.02 [1.24, 3.3] | 2 studies · 964 participants | High |
Proportion of patients achieving DAS <2.6 (Remission) Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | OR 3.88 [2.33, 6.45] | 2 studies · 957 participants | High |
Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | no estimate extracted | 2 studies · 859 participants | High |
All Withdrawals: Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | RR 0.39 [0.36, 0.43] | 5 studies · 2107 participants | High |
Withdrawals due to adverse events Summary of findings certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX) | OR 1.93 [1.15, 3.23] | 4 studies · 2071 participants | High |